# 1. Financial Performance ## A. Key Figures * Revenue: ₹65.77 Cr (Q3 Dec-2025) (+20%) · ₹12.61 Cr EBITDA (+39%) (19.17% margin, +263 bps) * PAT: ₹4.54 Cr (Q4 Dec-2025) (+8% QoQ) (6.9% margin, -7.7 bps) ## B. Revenue Growth * **Solid Top-Line Momentum:** Revenue growth at 20% YoY reflects sustained demand and effective market positioning. ## C. EBITDA & Margins * **Strong Margin Expansion:** EBITDA margin improved significantly on operating leverage and cost discipline, despite a **one-time gratuity expense of INR 2 Cr** linked to the new labour code. * **Non-Recurring Pressure:** The exceptional loss of **INR 2 Cr** for employee gratuity due to wage revisions is not expected to repeat, supporting margin normalization. ## D. Profit After Tax * **Robust Bottom-Line Growth:** PAT surged 97% QoQ on strong earnings momentum, though margin dipped slightly due to the **INR 2 Cr** non-recurring gratuity provision. ## E. Cash Flow Trends * **Improving Working Capital:** Working capital days are trending downward QoQ, indicating better operational efficiency despite a weak base. * **Positive Cash Outlook:** Company on track to deliver **positive net cash inflow from operations** this fiscal, enhancing financial flexibility. --- # 2. Business Model & Segments ## A. Key Figures * **Revenue Mix Target:** 33% B2C · 33% B2B · 33% B2G (short-term range: 30–40%) * **Franchisee Agreements Signed:** **>100** (launch over next 6 months) · Target of **1,000 within 3 years** * **Diagnostic vs Pharmacy Revenue Mix:** **60:40** (Q3) * **Consolidated EBITDA Margin:** **19–20%** (impacted by pharmacy) ## B. B2C, B2B, B2G Mix * **Strategic Mix Discipline:** Management targets a balanced one-third split across B2C, B2B, and B2G, allowing flexibility to capture market opportunities within a 30–40% band. * **Margin Leadership in B2C:** B2C delivers the highest segment margins, with mature centers exceeding **45% EBITDA**, reinforcing strategic focus on comprehensive diagnostic centers. * **Working Capital Advantage:** Government-linked patient transactions are treated as B2C with direct patient payments, preserving cash flow and minimizing working capital strain. ## C. Franchisee Expansion * **Aggressive Franchise Rollout:** Company has signed **over 100 franchisee agreements** in recent months, marking a strategic shift from a 100% non-franchise model, with operations ramping over the next six months. * **Sustainable Unit Economics:** Franchise model is capital-light and scalable, with new centers typically reaching **break-even within one year**, supported by centralized guidance on referral incentives. * **Differentiated Model vs Peers:** Unlike Dr. Lal PathLabs, Chandan does not rely on external referral franchises; instead, it directly operates centers and now expands via owned franchise units, enhancing control and service quality. ## D. Diagnostic vs Pharmacy * **Diagnostics as Core Growth Engine:** Diagnostic B2C sales drove strong double-digit revenue growth, with the segment alone delivering **over 30% EBITDA margin** and targeting expansion to **>35%** next year. * **Pharmacy as Strategic Enabler:** Despite minimal current EBITDA and a low-margin profile, pharmacy units serve as **key sample collection points**, creating operational synergy and justifying continued investment despite limited standalone profitability. * **Long-Term Mix Guidance:** Company plans to cap pharmacy at **10–20% of total revenue** over 3–5 years while scaling diagnostics, aligning with margin optimization goals. --- # 3. Capacity & Expansion ## A. Key Figures * **New Labs Launched in FY'26:** **18** company-owned labs · **7** comprehensive diagnostic centres * **Total Labs Network:** **60** labs including comprehensive centres * **Fundraising:** **₹104 Cr** via preferential shares (**₹26 Cr received**, **₹78 Cr expected within 1 year**) ## B. New Labs & Centers * **Aggressive Rollout Pace:** Expansion on track with **nine new labs** and **one comprehensive centre (Raipur)** launching imminently, signaling strong execution momentum. * **Scaled Network Impact:** Launch of **comprehensive centres and labs** expected to drive **significant EBITDA margin improvement next year** due to operational scale. * **Preventive Care Push:** **Two wellness centres** launching next month in Delhi and Raipur to capture growing demand for holistic and preventive health services. * **Advanced Capabilities:** A **centralized genetic lab in Lucknow** will be operational in 3–6 months, enabling pan-India advanced testing with capital-efficient reach. ## C. Geographic Rollout * **Franchise-Led National Reach:** Plans to establish **~1,000 franchisee diagnostic centres** with zero capex, accelerating footprint expansion. * **Strategic Focus on Smaller Cities:** Expansion prioritizes **Tier 2, Tier 3, and Tier 4 cities** where organized healthcare access is limited, driving first-mover advantage. * **Radiology Revenue Growth:** Expansion in **Punjab and Guwahati**, including government hospital partnerships, poised to increase **radiology’s share of revenue** over time. ## D. Capex & Infrastructure * **Self-Funded Expansion:** Raised **₹104 Cr via preferential shares**, fully subscribed and sufficient to cover **next year’s capex** with no equity dilution expected for 2–3 years. * **Infrastructure Buildout:** Most labs are standalone (higher capex), though select units within **Jeena Sikho Hospitals** benefit from space support, optimizing costs. * **Future-Ready Facilities:** Pipeline includes **three more comprehensive centres**, a **PET scan facility in Gorakhpur**, and a **genome lab in Lucknow**. --- # 4. Customer & Revenue Drivers ## A. Key Figures * Daily Collections: ₹2.5–3 Lakh from Jeena Sikho hospitals (25–30% network coverage) * **Government Contract Value:** **₹55 Cr/year** (Punjab & Guwahati), **10-year total: ₹550 Cr** * **Revenue Concentration:** **90%** from Tier 2/3 cities ## B. Patient Footfall & Demand Drivers * **Strong Organic Pull:** High direct patient footfall driven by **service quality, competitive pricing**, and middle-class affordability, with growing self-referrals and repeat visits. * **Referral Network Depth:** **Half of all patients** come via doctor referrals, supported by affiliations with **200+ physicians**, enabling scalable patient acquisition. * **Customer Loyalty & Expansion:** Early evidence of **multi-member enrollment** and **planned biannual checkups** indicates strong retention potential and wallet share growth. ## C. Corporate & Insurance Partnerships * **Stable, High-Volume Pipeline:** Corporate and insurance clients provide **reliable, recurring revenue** with favorable payment cycles (1–45 days), though CGHS lags. * **Strategic Contract Wins:** Secured **major multi-year contract** through competitive bidding on CGHS rates, setting foundation for **quarterly growth acceleration**. ## D. Government Projects & PPP Model * **Game-Changing PPP Structure:** Punjab and Guwahati projects operate on **patient-pay, rent-free model**, eliminating government billing risk and ensuring **direct cash flow capture**. * **Upside Beyond Tender Value:** Historical precedent shows **actual revenue can exceed estimates 8x**, suggesting **₹55 Cr/year contract may significantly outperform**. * **Scalable Infrastructure Rollout:** **MRI/CT installations in nine district hospitals** within six months will expand access and volume base in underserved regions. --- # 5. Product & Service Mix ## A. Key Figures * Pathology Revenue Mix: 75% of diagnostics revenue at the moment · Radiology: 25% (shift expected) * **Closed-System Cost:** **INR12,000** investment for a **INR25,000**-priced test ## B. Pathology & Radiology * **Integrated Model Advantage:** Dominant presence in comprehensive centres offering both pathology and radiology under one roof, a differentiated model with no major national competitors. * **Radiology Differentiation:** Strong competitive edge in radiology vs. Dr. Lal Pathlabs and Vijaya Diagnostics, which focus primarily on sample-based testing via franchises. * **On-Site Imaging Edge:** Operational advantage from on-site radiology services, contrasting with peers’ centralized, remote lab models. * **Patient Trust Premium:** High client retention driven by reputation for **accurate reports**, with customers willing to pay slight price premiums for reliability. ## C. Wellness & Genetic Testing * **Strategic Growth Focus:** Molecular diagnostics identified as a key future driver, aligned with rising demand in **cancer, IVF, and genetic testing**. ## D. Closed-System Adoption * **Quality Over Cost:** Shift to closed-system PCR machines prioritizes **higher accuracy and precision** in critical applications like cancer and IVF, despite higher input costs. --- # 6. Risks & Execution Challenges ## A. Margin Pressure * **One-Time Gravitas Hit:** Gratuities provisioning created a non-recurring expense, with no expected repeat impact on margins in coming quarters. * **Elevated Cost Curve:** Employee costs rose meaningfully to **18% of revenues** (from 14%-15%), raising investor concerns over sustainability of cost advantage in Tier 1/2 cities. * **Pricing Policy Clarity:** Reintroduction of promotional schemes has no bearing on investment thesis; prior pricing adjustments were strategic, not margin-dilutive. ## B. Integration Delays * **Execution Confidence:** Expansion faces no material execution risks, supported by dedicated team of **40 employees** and fully internalized funding. ## C. Pricing Competition * **Franchisee Segment Limited:** Competitive pressure from Dr. Lal, Thyrocare, and Metropolis confined to **10% of business**, mitigating systemic threat. * **Structural Moat Intact:** Outperforms local pathologists/radiologists via **lower pricing, pan-India scale, strong branding, and full in-house testing capability**. * **Customer-Centric Pricing Review:** Management open to eliminating **>5 km sample collection fee** following feedback on customer friction vs. peers. --- # 7. Guidance & Outlook ## A. Key Figures * **Top-Line Growth Guidance:** **>30%** expected next fiscal * **Franchise Expansion Target:** **1,000 franchisees** in three years * **EBITDA Margin Target:** **30%–35%** sustainable range expected * **Planned Facilities (Next Year):** **3 comprehensive centers**, **13 labs**, **1 genome lab**, **1 PET scan center**, **1 wellness center** ## B. Top-Line Forecast * **Robust Growth Trajectory:** Management expects significantly above 30% top-line growth next year, with Q4 anticipated to mark a turning point in performance visibility. * **Market Positioning:** Aims to rank among the **top four or five** diagnostic chains in India within 2–3 years, constrained from reaching top two/three by entrenched competitors. ## C. Margin Trajectory * **Margin Recovery Path:** EBITDA margins expected to improve progressively from Q4 onward, supported by operational scaling despite near-term expansion pressures. * **Structural Margin Support:** Sustainable 30%–35% EBITDA margins anticipated long-term, underpinned by diversified **B2C, B2B, and corporate revenue mix**. ## D. Expansion Pipeline * **Network-Led Growth:** Franchise-driven expansion of 1,000 outlets over three years to fuel sample inflow and geographic reach, enhancing collection scale post-integration. * **Strategic Facility Rollout:** Flagship investments include first **PET scan center (Gorakhpur)** and **Genome lab (Lucknow)**, targeted for H1 2027, elevating service capability. * **Capital Discipline:** Expansion pace moderating next year to prioritize profitability and return realization after heavy outlays this year. * **Societal Initiatives Reinstated:** Health checkup promotion scheme reinstated to drive preventive care, reflecting long-term customer acquisition over short-term margin trade-offs.